Nachrichten zur Poseida Therapeutics Aktie

Roche to complete acquisition of U.S. biopharma company Poseida

Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue…

Roche set to finalise $1.5bn Poseida Therapeutics takeover

Swiss healthcare firm Roche has said its US$1.5 billion takeover of US biopharmaceutical company Poseida Therapeutics will be completed on…

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

Basel, 9 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for…

PBF Energy, Poseida Therapeutics, and More Stocks See Action From Activist Investors

…

Poseida Therapeutics Aktie: Tolle Perspektiven für Anleger!

Die Poseida Therapeutics Aktie verzeichnete im November 2024 eine bemerkenswerte Entwicklung an den Börsen. Mit einem aktuellen Kurs von 9,31…

Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet

The consensus price target hints at a 49.3% upside potential for Poseida Therapeutics (PSTX). While empirical research shows that this…

Poseida Therapeutics: What The Acquisition Offer Says About Big Pharma Priorities

…

Pharma-Deal: Roche baut Zelltherapie mit Übernahme von US-Biotechfirma aus

Der Schweizer Konzern will Poseida Therapeutics um bis zu 1,5 Milliarden Euro aufkaufen. Das kalifornische Unternehmen arbeitet unter anderem an Therapien…

Roche to acquire Poseida Therapeutics for $1.5bn

…

Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion

…

Roche to acquire US-based Poseida Therapeutics By Reuters

Roche to acquire US-based Poseida Therapeutics…

Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B

RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.…

Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024

…

Poseida Therapeutics: Non-Self CAR T Looks To Be Safe And Potentially Impactful

…

Poseida Therapeutics: Why I Am Still Holding On To The Stock Into 2024 (Rating Downgrade)

…

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 39.62% and 100.13%, respectively, for the quarter ended June 2023.…

XFRA : 2RZ: Aussetzung/Suspension

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

XFRA : 2RZ: Wiederaufnahme/Resumption

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

Poseida jumps on $50M investment from Astellas

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Poseida Therapeutics Shares Leap on Astellas Investments >PSTX

Poseida Therapeutics Shares Leap on Astellas Investments >PSTX...…

Poseida Therapeutics in $50 Million Investment Deal With Astellas >PSTX

Poseida Therapeutics in $50 Million Investment Deal With Astellas >PSTX...…

XFRA : INSTRUMENT_SUSPENSION - US73730P1084

Instrument ID [4168170] (2RZ - US73730P1084) suspended...…

Form 8-K Poseida Therapeutics, For: Aug 04

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Poseida gains on FDA nod to start trials for CAR-T therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Poseida Therapeutics to join Russell 3000 and Russell 2000 indexes

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Poseida Therapeutics, For: May 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

What Makes Poseida Therapeutics, Inc. (PSTX) a New Buy Stock

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings…

Poseida Therapeutics: Q1 Earnings Insights

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023

Highlighted significant research, preclinical advances and platform technology progress at third annual R&D Day Appointed Kristin Yarema, Ph.D., as President,…

Poseida Therapeutics Appoints Rafael G. Amado, M.D., to Board of Directors

SAN DIEGO, April 13, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing…

Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy

SAN DIEGO, April 11, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing…

Form 8-K Poseida Therapeutics, For: Mar 27

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Pre-market Movers: PSTX, NYCB, CVRX, FRC, PACW.

BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Mondays pre-market trading (as of 07.45…

Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Misses Revenue Estimates

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -182.98% and 71.28%, respectively, for the quarter ended December 2022.…

Poseida Therapeutics GAAP EPS of -$0.39 misses by $0.56, revenue of $10.05M misses by $21.7M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 10-K Poseida Therapeutics, For: Dec 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Poseida Therapeutics, For: Mar 09

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022

Presented early data from Phase 1 trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 allogeneic CAR-T cell therapy programs at the European Society…

Poseida stock falls ~8% postmarket after founder, executive chairman to step down

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Poseida Therapeutics, For: Jan 26

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Poseida Therapeutics Announces Board Change

Eric Ostertag, M.D., Ph.D., Founder and current Executive Chairman, to retire from the Board of Directors and remain a consultant…

Poseida Therapeutics Ushers New Era For Gene Therapies, Analyst Initiating Coverage Says

Latest Ratings for PSTX DateFirmActionFromTo Jan 2022Cantor FitzgeraldInitiates Coverage OnOverweight May 2021BTIGInitiates Coverage OnBuy Aug 2020B of A SecuritiesInitiates…

dpa-AFX ProFeed